esomeprazole magnesium
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endoscopically-Proven GERD
Conditions
Endoscopically-Proven GERD, Reflux
Trial Timeline
Aug 1, 2006 → May 1, 2008
NCT ID
NCT00687245About esomeprazole magnesium
esomeprazole magnesium is a phase 1 stage product being developed by AstraZeneca for Endoscopically-Proven GERD. The current trial status is completed. This product is registered under clinical trial identifier NCT00687245. Target conditions include Endoscopically-Proven GERD, Reflux.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00443963 | Approved | Withdrawn |
| NCT00687245 | Phase 1 | Completed |
| NCT00637559 | Approved | Completed |